Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| 5.05 Delayed Data As of Apr 09 |  -0.085 / -1.66%Today’s Change | 2.83 Today|||52-Week Range 13.40 | -6.40% Year-to-Date |
Latest ADAP News | Press Releases
No recent news for Adaptimmune Therapeutics PLC.
Today’s Trading
| Previous close | 5.13 |
| Today’s open | 5.03 |
| Day’s range | 4.99 - 5.37 |
| Volume | 27,961 |
| Average volume (3 months) | 1,309,057 |
| Market cap | $854.8M |
Data as of 3:59pm ET, 04/09/2021
Growth & Valuation
| Earnings growth (last year) | +29.87% |
| Earnings growth (this year) | -550.00% |
| Earnings growth (next 5 years) | +5.60% |
| Revenue growth (last year) | +254.04% |
| P/E ratio | NM |
| Price/Sales | 192.51 |
| Price/Book | 2.50 |
Competitors
Data as of 4:00pm ET, 04/09/2021
Financials
| Next reporting date | May 12, 2021 |
| EPS forecast (this quarter) | -$0.25 |
| Annual revenue (last year) | $4.0M |
| Annual profit (last year) | -$131.1M |
| Net profit margin | -3,286.81% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Abingdon, Oxfordshire |
Forecasts
